Clinical Trial Update: To Evaluate Immunogenicity, Reactogenicity & Safety of 2 Doses of GSK Bio HRV Liquid Vaccine Given to Infants (Vietnam) [Phase 3]

View source ↗

Summary

Phase 3 trial update assessing the immunogenicity, reactogenicity, and safety of two doses of GSK's HRV rotavirus vaccine given to infants in Vietnam.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rotavirus Infection

Drugs mentioned

• Rotarix (Rotavirus vaccine (live attenuated))

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Rotavirus | Phase 3 | Status: COMPLETED